Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RED-CABG trial of acadesine in high-risk CABG surgery
2008-004881-16Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of acadesine in coronary arteriosclerosis (2 arms), sponsored by Merck & Co. Primary endpoint: Composite of all-cause death, severe left ventricular dysfunction, or non-fatal stroke through postoperative day 28. Started Apr 2009; status: terminated.
02
Drugs
acadesine
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2008-004881-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004881-16.